Get started
Author

Nicolaas A. Verwey

Observed names: N A Verwey, N. A. Verwey, N. Verwey, N.A. Verwey, Nicolaas A Verwey, Nicolaas Verwey, Verwey, N. A., Verwey, Nicolaas A.
Institutions: University Medical Center Groningen, University of Groningen, Medisch Centrum Leeuwarden, Amsterdam Neuroscience, Frisius MC, Vrije Universiteit Amsterdam, University of Amsterdam
Observed institutions: Leiden University, University Medical Center Groningen, Université Toulouse III - Paul Sabatier, University of Groningen, Utrecht University, Leiden University Medical Center, Medisch Centrum Leeuwarden, Amsterdam UMC Location University of Amsterdam, Amsterdam Neuroscience, GGZ inGeest, Haga Hospital, Amsterdam University Medical Centers, Medisch Centrum Alkmaar, Frisius MC, UCL Queen Square Institute of Neurology, University College London, Vrije Universiteit Amsterdam, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Edinburgh
ORCID: 0000-0003-0013-6672
Observed ORCID: 0000-0003-0013-6672
OpenAlex ID: A5110639722
Assessment of cognition in Parkinson’s disease
2003 · J. Marinus, M. Visser, et al. · Neurology · 339
Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
2009 · Cees Mulder, Nicolaas A Verwey, et al. · Clinical Chemistry · 335
PDF
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
2011 · N.S.M. Schoonenboom, F.E. Reesink, et al. · Neurology · 304
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
2009 · N A Verwey, W M van der Flier, et al. · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · 169
Relationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
2009 · Nelleke Tolboom, Wiesje M. van der Flier, et al. · Journal of Nuclear Medicine · 160
PDF
CSF biomarker levels in early and late onset Alzheimer's disease
2008 · Femke H. Bouwman, Niki S.M. Schoonenboom, et al. · Neurobiology of Aging · 142
Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
2018 · Eline A.J. Willemse, Ingrid S. van Maurik, et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 106
PDF
CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
2009 · A. E. van der Vlies, N. A. Verwey, et al. · Neurology · 106
Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
2015 · Yolande A.L. Pijnenburg, Nicolaas A. Verwey, et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 91
PDF
Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease
2009 · W.J.P. Henneman, H. Vrenken, et al. · Neurology · 76
PDF
Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
2011 · Maartje I. Kester, Peter G. Scheffer, et al. · Neurobiology of Aging · 63
PDF
Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease
2011 · Jeroen D.C. Goos, Charlotte E. Teunissen, et al. · Neurobiology of Aging · 59
Cerebrospinal Fluid β‐Amyloid and Tau Are Not Associated with Risk of Delirium: A Prospective Cohort Study in Older Adults with Hip Fracture
2011 · Joost Witlox, Kees J. Kalisvaart, et al. · Journal of the American Geriatrics Society · 51
New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population
2010 · F.H. Bouwman, N.A. Verwey, et al. · Dementia and Geriatric Cognitive Disorders · 51
Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study
2016 · H. Bea Kuiperij, Alexandra A.M. Versleijen, et al. · Journal of Alzheimer s Disease · 46
Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease
2008 · Nicolaas A. Verwey, Alie Schuitemaker, et al. · Dementia and Geriatric Cognitive Disorders · 36
Additional Value of CSF Amyloid-β40 Levels in the Differentiation between FTLD and Control Subjects
2010 · Nicolaas A. Verwey, Maartje I. Kester, et al. · Journal of Alzheimer s Disease · 34
Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia
2012 · Esther L.G.E. Koedam, Annelies E. van der Vlies, et al. · Alzheimer s & Dementia · 22
Quantification of amyloid-beta 40 in cerebrospinal fluid
2009 · Nicolaas A. Verwey, Robert Veerhuis, et al. · Journal of Immunological Methods · 22
Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
2008 · Maartje I. Kester, Nicolaas A. Verwey, et al. · Neurobiology of Aging · 21
Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide
2013 · Nicolaas A. Verwey, Jeroen J.M. Hoozemans, et al. · Amyloid · 20
Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
2008 · Nicolaas A. Verwey, Femke H. Bouwman, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 16
Recognition of cognitive dysfunction in hospitalised older patients: a flash mob study
2024 · Fleur C. W. Visser, Marlise E. A. van Eersel, et al. · BMC Geriatrics · 14
PDF
Hodges' Frontotemporal Dementia
2015 · John R. Hodges, Paul McMonagle, et al. · Cambridge University Press eBooks · 14
Progression from MCI to AD: Predictive value of CSF Aβ42 is modified by APOE genotype
2009 · Maartje I. Kester, Nicolaas A. Verwey, et al. · Neurobiology of Aging · 14
Works count: 55
Citation count: 2,369
H-index: 20
I10-index: 26
Year
Topic
Type